Acorn Biolabs, a personalized regenerative medicine company that offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a patient’s own cells, today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 12,058,997 for Acorn’s liquid preservation solution, which is designed to protect the integrity of cell and tissue samples during transportation and during cryogenic storage.  

“This patent supports Acorn’s vision to build a regenerative medicine platform that is accessible, scalable, and trusted as personalized, stem-cell treatments and research become increasingly relevant in healthcare,” said Drew Taylor, MSc, PhD, CEO of Acorn Biolabs. “In addition to supporting our cryopreservation business, we have leveraged our novel solution in partnership with leading research institutions where there has been a gap in the reliable handling of biological research samples during transportation between locations.”

Powering Acorn’s regenerative medicine platform is its cryogenic stem cell banking service, which allows people to safely store stem cells derived from their own hair follicles for their lifetime. These cells can be used in the short term to create personalized topical skin and hair care treatments. In the future, these same cells may be used as personalized stem-cell therapies become available across an array of therapeutic areas. Acorn launched its stem cell banking service in North America in 2023 and is currently partnered with more than 70 clinics. 

This patent is the first granted for Acorn’s liquid preservation solution. The company has several additional patent applications currently under review.